Published in:
Open Access
01-04-2023 | Disease Modifying Anti-Rheumatic Drug | Commentary
Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
Authors:
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
Published in:
Rheumatology and Therapy
|
Issue 2/2023
Login to get access
Excerpt
Psoriatic arthritis (PsA) is a complex and chronic inflammatory disease characterized by an association of psoriasis and arthritis in which different manifestations run together during the disease course [
1,
2]. Recent GRAPPA and EULAR recommendations [
3,
4] were published on the treatment management of PsA, based on over 20 years of active research that have led to the development of efficacious and effective drugs to treat all disease domains. Biologic DMARDs (anti-TNF, anti-IL-12/23, anti-IL-23, anti-IL-17) and the new targeted synthetic DMARDs (JAK inhibitors- JAKi such as tofacitinib, upadacitinib and PDE4 inhibitor—apremilast) revolutionized the treatment of PsA with proved efficacy and effectiveness in the achievement of remission, low disease activity and in a “comprehensive” disease control (efficacy on almost all disease domains) [
3]. …
